

Company Overview

Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on protein homeostasis via the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe autoimmune diseases. Additionally, KZR-261 is the first clinical candidate for the treatment of cancer from our protein secretion program and is undergoing IND-enabling activities for the program.

Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology

Sep 17 2020, 4:01 PM EDT

Kezar Life Sciences to Present at The Myositis Association International Annual Patient Conference and the Pan-American Congress of Rheumatology

Sep 10 2020, 7:00 AM EDT

Kezar Life Sciences to Participate in Upcoming Virtual Investor Conferences

Sep 3 2020, 4:26 PM EDT

Stock Overview

Symbol	KZR
Exchange	Nasdaq
Market Cap	208.62m
Last Price	\$4.51
52-Week Range	\$2.18 - \$9.79

09/25/2020 04:00 PM EDT

Investor Relations

Celia Economides
IR@kezarbio.com

Management Team

John Fowler

CEO, Co-Founder

Christopher Kirk, Ph.D

President and CSO, Co-Founder

Noreen R. Henig, M.D.

Chief Medical Officer

Marc L. Belsky

Chief Financial Officer

Celia Economides

Senior Vice President of Strategy and External Affairs

Kezar Life Sciences, Inc.

4000 Shoreline Court
Suite 300
South San Francisco, CA 94080

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.